GlassScriptPhysician profile
Karo Torosian
NPI 1275822082
$1,255.85
in general payments reported to CMS, 2019-2025
17 companies · $44.63 in 2025
The $44.63 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $147 · 2021: $175 · 2022: $398 · 2023: $16.26 · 2024: $33.48 · 2025: $44.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $76.45 · Education: $17.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $76.45 |
| Education | $17.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $283.32 | 2019-2022 | |
| Nxstage Medical, INC. | $202.18 | 2022-2025 | Nxstage System One, Liberty Select Cycler |
| Vifor Pharma, INC. | $146.07 | 2019-2022 | |
| Akebia Therapeutics INC | $131.60 | 2019 | |
| Amgen INC. | $114.67 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $63.46 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $60.52 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.51 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $46.15 | 2019-2021 | |
| Veloxis Pharmaceuticals, INC. | $41.67 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $31.21 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.20 | 2019 | |
| Boston Scientific Corporation | $14.09 | 2019 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $4.32 | 2023-2025 | Filspari |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karo Torosian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.